Source-grounded facts extracted from CalciMedica, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Parisa Zamiri was terminated as Chief Medical Officer at CalciMedica, Inc..
“On February 28, 2023, the Board of Directors of Graybug Vision, Inc. (“Graybug”) determined it to be in Graybug’s best interests to terminate Parisa Zamiri’s employment in advance of the anticipated closing date of the Merger”
CalciMedica, Inc. amended First Amendment with Graybug, CalciMedica and Camaro Merger Sub, Inc. (effective 2023-02-10).
“In connection with the Note Purchase Agreement, on February 10, 2023, Graybug, CalciMedica and Camaro Merger Sub, Inc. (“Camaro Merger Sub”) entered into a First Amendment (the “Amendment”) to the Agreement and Plan of Merger and Reorganization (the “Merger Agreement”)”
CalciMedica, Inc. entered into Note Purchase Agreement with Graybug Vision, Inc. valued at $2.0 million (effective 2023-02-10).
“On February 10, 2023, Graybug Vision, Inc. (“Graybug”) and CalciMedica, Inc. (“CalciMedica”) entered into a note purchase agreement (the “Note Purchase Agreement”) providing for Graybug to make short-term loans (the “Loan” or “Loans”) to CalciMedica up to an aggregate principal amount of $2.0 million”
Eric Bjerkholt was appointed as Class I Director at CalciMedica, Inc..
“Eric Bjerkholt, a current Class II member of the Board, submitted a letter to resign from the Board and was re-appointed as a Class I director, in each case, contingent upon the Closing and effective as of the Effective Time.”
Dirk Sauer resigned as Director at CalciMedica, Inc..
“the Board received letters from Christy Shaffer, Ph.D., Christina Ackermann, Julie Eastland and Dirk Sauer, Ph.D., resigning as directors of the Company and as members of the Committees of the Board, contingent upon the Closing and effective as of the Effective Time”
Julie Eastland resigned as Director at CalciMedica, Inc..
“the Board received letters from Christy Shaffer, Ph.D., Christina Ackermann, Julie Eastland and Dirk Sauer, Ph.D., resigning as directors of the Company and as members of the Committees of the Board, contingent upon the Closing and effective as of the Effective Time”
Christina Ackermann resigned as Director at CalciMedica, Inc..
“the Board received letters from Christy Shaffer, Ph.D., Christina Ackermann, Julie Eastland and Dirk Sauer, Ph.D., resigning as directors of the Company and as members of the Committees of the Board, contingent upon the Closing and effective as of the Effective Time”
Christy Shaffer resigned as Director at CalciMedica, Inc..
“the Board received letters from Christy Shaffer, Ph.D., Christina Ackermann, Julie Eastland and Dirk Sauer, Ph.D., resigning as directors of the Company and as members of the Committees of the Board, contingent upon the Closing and effective as of the Effective Time”
Robert N. Wilson was appointed as Chair of the Board at CalciMedica, Inc..
“Robert N. Wilson will be the Chair of the Board.”
Allan Shaw was appointed as Director at CalciMedica, Inc..
“unanimously approved the appointment of A. Rachel Leheny, Ph.D., Eric W. Roberts, Robert N. Wilson, Fred Middleton and Allan Shaw, aged 59, 59, 82, 73 and 58, respectively, to serve as members of the Board, contingent upon the Closing and effective as of the Effective Time”
Fred Middleton was appointed as Director at CalciMedica, Inc..
“unanimously approved the appointment of A. Rachel Leheny, Ph.D., Eric W. Roberts, Robert N. Wilson, Fred Middleton and Allan Shaw, aged 59, 59, 82, 73 and 58, respectively, to serve as members of the Board, contingent upon the Closing and effective as of the Effective Time”
Robert N. Wilson was appointed as Director at CalciMedica, Inc..
“unanimously approved the appointment of A. Rachel Leheny, Ph.D., Eric W. Roberts, Robert N. Wilson, Fred Middleton and Allan Shaw, aged 59, 59, 82, 73 and 58, respectively, to serve as members of the Board, contingent upon the Closing and effective as of the Effective Time”
Eric W. Roberts was appointed as Director at CalciMedica, Inc..
“unanimously approved the appointment of A. Rachel Leheny, Ph.D., Eric W. Roberts, Robert N. Wilson, Fred Middleton and Allan Shaw, aged 59, 59, 82, 73 and 58, respectively, to serve as members of the Board, contingent upon the Closing and effective as of the Effective Time”
A. Rachel Leheny was appointed as Director at CalciMedica, Inc..
“unanimously approved the appointment of A. Rachel Leheny, Ph.D., Eric W. Roberts, Robert N. Wilson, Fred Middleton and Allan Shaw, aged 59, 59, 82, 73 and 58, respectively, to serve as members of the Board, contingent upon the Closing and effective as of the Effective Time”
CalciMedica, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).
“December 27, 2022, Graybug Vision, Inc. (“Graybug” or the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that, based on the closing bid price of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), for the last 30 consecutive trading days, the Company no longer complies with the minimum bid price requirement for continued listing on The Nasdaq Global Market. Nasdaq Listing Rule 5450(a)(1) requires listed securities to maintain a minimum bid price of $1.00 per share”
CalciMedica, Inc. entered into Agreement and Plan of Merger and Reorganization with CalciMedica, Inc. (effective 2022-11-21).
“On November 21, 2022, Graybug Vision, Inc., a Delaware corporation (“ Graybug ”), entered into an Agreement and Plan of Merger and Reorganization (the “ Merger Agreement ”) with CalciMedica, Inc., a Delaware corporation (“ CalciMedica ”), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies for serious inflammatory diseases with high unmet need, and Camaro Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Graybug (“ Merger Sub ”).”
CalciMedica, Inc. reported the nine months ended September 30, 2022 results: net income $28.2 million.
“Net loss for the nine months ended September 30, 2022 was $28.2 million”
CalciMedica, Inc. reported the quarter ended September 30, 2022 results: net income $9.8 million.
“Net loss for the quarter ended September 30, 2022 was $9.8 million”
Dirk Sauer was appointed as Director at CalciMedica, Inc..
“On April 13, 2022 (the “Effective Date”) , the Board, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Dirk Sauer, Ph.D, age 62, to serve as a member of the Board to fill the vacancy that was created by the resignation of Dr. Cagle described above.”
Gerald D. Cagle resigned as Director at CalciMedica, Inc..
“On April 13, 2022, the Board of Directors (the “Board”) of Graybug Vision, Inc. (the “Company”) received a letter from Gerald D. Cagle, Ph.D resigning as a director of the Company and as a member of the Nominating and Corporate Governance Committee of the Board, effective as of that day.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.